This 2015 study explores the potential of artesunate (ART), an anti-malarial drug, as a treatment for metastatic renal cell carcinoma (RCC). Analysis of patient data revealed that high expression of transferrin receptor 1 (TfR1), a marker associated with ART sensitivity, correlated with distant metastasis and poor prognosis in clear cell
